Literature DB >> 27987345

Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes.

Michiko Kubo1, Takashi Umekawa1, Yuka Maekawa2, Hiroaki Tanaka1, Masafumi Nii1, Nao Murabayashi1, Kazuhiro Osato1, Yuki Kamimoto1, Tomoaki Ikeda1.   

Abstract

AIM: The aim of this retrospective study was to assess tadalafil treatment in pregnant women with fetal growth restriction (FGR) in terms of maternal and perinatal outcomes.
METHODS: We retrospectively analyzed 11 Japanese singleton pregnant women with FGR who received tadalafil along with conventional management for FGR at Mie University Hospital from July 2015 to February 2016 (tadalafil group). These women were matched for maternal age, parity, gestational age, and estimated fetal weight at enrollment with 14 singleton pregnant women who received only the conventional management for FGR in 2014 (conventional management group). The conventional management for FGR was performed according to guidelines for obstetric practice in Japan.
RESULTS: Both birthweight and fetal growth velocity from enrollment to birth were significantly higher in the tadalafil group than in the conventional management group. The cesarean delivery rate was approximately twofold higher in the conventional management group than in the tadalafil group. Importantly, cesarean section due to non-reassuring fetal status was performed in seven pregnant women in the conventional management group (58.3%) but in none in the tadalafil group (P < 0.05, chi-squared test).
CONCLUSIONS: Tadalafil may improve perinatal outcome in FGR by modulating fetal growth through maintenance or improvement of fetal well-being.
© 2016 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  fetal growth restriction; fetal growth velocity; phosphodiesterase 5 inhibitor; retrospective study; tadalafil

Mesh:

Substances:

Year:  2016        PMID: 27987345     DOI: 10.1111/jog.13218

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  8 in total

1.  Tadalafil treatment for fetuses with early-onset growth restriction: a protocol for a multicentre, randomised, placebo-controlled, double-blind phase II trial (TADAFER IIb).

Authors:  Shintaro Maki; Hiroaki Tanaka; Sho Takakura; Masafumi Nii; Kayo Tanaka; Toru Ogura; Mayumi Kotera; Yuki Nishimura; Satoshi Tamaru; Takafumi Ushida; Yasuhiro Tanaka; Norihiko Kikuchi; Tadatsugu Kinjo; Hiroshi Kawamura; Mayumi Takano; Koji Nakamura; Sachie Suga; Michi Kasai; Osamu Yasui; Kenji Nagao; Yuka Maegawa; Tomomi Kotani; Masayuki Endo; Ichiro Yasuhi; Shigeru Aoki; Yoichi Aoki; Yoshio Yoshida; Masahiko Nakata; Akihiko Sekizawa; Tomoaki Ikeda
Journal:  BMJ Open       Date:  2022-06-14       Impact factor: 3.006

2.  Pregnancy in Congenital Heart Disease, Complicated by Pulmonary Arterial Hypertension-A Challenging Issue for the Pregnant Woman, the Foetus, and Healthcare Professionals.

Authors:  Virginija Rudienė; Lina Kaplerienė; Dovilė Jančauskaitė; Emilija Meškėnė; Eglė Palevičiūtė; Monika Laukytė-Slėnienė; Diana Gasiūnaitė; Diana Ramašauskaitė; Elena Jurevičienė; Lina Gumbienė
Journal:  Medicina (Kaunas)       Date:  2022-03-25       Impact factor: 2.948

3.  Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions.

Authors:  Ryota Tachibana; Takashi Umekawa; Kento Yoshikawa; Takao Owa; Shoichi Magawa; Fumi Furuhashi; Makoto Tsuji; Shintaro Maki; Kyoko Shimada; Michiko K Kaneda; Masafumi Nii; Hiroaki Tanaka; Kayo Tanaka; Yuki Kamimoto; Eiji Kondo; Ineko Kato; Kenji Ikemura; Masahiro Okuda; Ning Ma; Takekazu Miyoshi; Hiroshi Hosoda; Masayuki Endoh; Tadashi Kimura; Tomoaki Ikeda
Journal:  Sci Rep       Date:  2019-01-18       Impact factor: 4.379

4.  Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy.

Authors:  Hiroaki Tanaka; Shintaro Maki; Shoichi Magawa; Masafumi Nii; Kayo Tanaka; Kenji Ikemura; Kuniaki Toriyabe; Tomoaki Ikeda
Journal:  Medicina (Kaunas)       Date:  2019-10-21       Impact factor: 2.430

5.  Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring.

Authors:  Takuya Kawamura; Hiroaki Tanaka; Ryota Tachibana; Kento Yoshikawa; Shintaro Maki; Kuniaki Toriyabe; Hiroki Takeuchi; Shinji Katsuragi; Kayo Tanaka; Tomoaki Ikeda
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

6.  Tadalafil Treatment Ameliorates Hypoxia and Alters Placental Expression of Proteins Downstream of mTOR Signaling in Fetal Growth Restriction.

Authors:  Kyoka Tsuchiya; Kayo Tanaka; Hiroaki Tanaka; Shintaro Maki; Naosuke Enomoto; Sho Takakura; Masafumi Nii; Kuniaki Toriyabe; Shinji Katsuragi; Tomoaki Ikeda
Journal:  Medicina (Kaunas)       Date:  2020-12-21       Impact factor: 2.430

7.  Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction.

Authors:  Shintaro Maki; Ineko Kato; Naosuke Enomoto; Sho Takakura; Masafumi Nii; Kayo Tanaka; Hiroaki Tanaka; Shinsuke Hori; Kana Matsuda; Yukito Ueda; Hirofumi Sawada; Masahiro Hirayama; Akihiro Sudo; Tomoaki Ikeda
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

8.  TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial.

Authors:  Takashi Umekawa; Shintaro Maki; Michiko Kubo; Hiroaki Tanaka; Masafumi Nii; Kayo Tanaka; Kazuhiro Osato; Yuki Kamimoto; Satoshi Tamaru; Toru Ogura; Yuki Nishimura; Mayumi Kodera; Chisato Minamide; Masakatsu Nishikawa; Masayuki Endoh; Tadashi Kimura; Tomomi Kotani; Masamitsu Nakamura; Akihiko Sekizawa; Tomoaki Ikeda
Journal:  BMJ Open       Date:  2018-10-30       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.